Karen Lewis is CPO at Apellis Pharmaceuticals, Inc. (APLS). They have made 8 open-market trades across 1 company since 2023, most recently 2025-01-29.
CIK 0001814304
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 70,251 | $2.9M |
Shares reported on the most recent Form 4, priced at the 2025-01-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL | 2025-01-29 | 2025-01-30 | $29.52 | $11K | -5.8% | -20.6% | -36.6% |
| APLS | SELL | 2025-01-22 | 2025-01-23 | $30.43 | $107K | -6.4% | -10.8% | -43.1% |
| APLS | SELL | 2025-01-17 | 2025-01-21 | $29.96 | $37K | -3.4% | -5.6% | -39.9% |
| APLS | SELL | 2025-01-13 | 2025-01-14 | $28.70 | $46K | +5.2% | -3.1% | -31.8% |
| APLS | SELL · 10b5-1 | 2024-01-29 | 2024-01-31 | $65.29 | $139K | +6.8% | +0.7% | -30.4% |
| APLS | SELL · 10b5-1 | 2024-01-23 | 2024-01-24 | $63.69 | $546K | +0.8% | +1.3% | -27.9% |
| APLS | SELL | 2024-01-22 | 2024-01-23 | $65.00 | $113K | -6.3% | +1.3% | -28.6% |
| APLS | SELL · 10b5-1 | 2024-01-17 | 2024-01-18 | $65.58 | $430K | +3.1% | +6.0% | -24.9% |
| APLS | SELL | 2024-01-16 | 2024-01-17 | $66.81 | $218K | -1.8% | +3.3% | -22.2% |
| APLS | SELL · 10b5-1 | 2023-06-01 | 2023-06-02 | $86.00 | $430K | +5.1% | +1.8% | -51.8% |
| APLS | SELL · 10b5-1 | 2023-04-03 | 2023-04-05 | $75.00 | $375K | +6.2% | +20.4% | +14.1% |
| APLS | SELL | 2023-02-23 | 2023-02-27 | $68.76 | $152K | -2.2% | +1.7% | +33.6% |
| APLS | SELL · 10b5-1 | 2023-01-30 | 2023-01-31 | $52.76 | $47K | -2.7% | +22.4% | +57.6% |
| APLS | SELL | 2023-01-23 | 2023-01-25 | $51.58 | $305K | +8.3% | +30.8% | +71.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.